Correction: BMC Complement Med Ther 19, 168 (2019)

https://doi.org/10.1186/s12906-019-2535-3

Following publication of the original article [1], the authors reported an error in Fig. 2. The correct figure is given below.

Fig. 2
figure 1

The viability of the hPBMC (measured by flow cytometry) isolated from blood of healthy subjects (control) (a) and psoriasis patients (b) following exposure to 20 µg/ml Naringin (Na), 100 µg/ml Sericin (Se), and Naringin/Sericin mixture 20/100 µg/ml compare with control (hPBMC from healthy subjects or psoriasis patients without exposure)

The original article [1] has been updated.